PMV Pharma, Merck Ink Clinical Trial Collaboration For Combination Study In Solid Tumors

• PMV Pharmaceuticals Inc (NASDAQ: PMVP) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK) to evaluate PC14586 in combination with Merck's Keytruda (pembrolizumab) for advanced solid tumors.

• PC14586 is a first-in-class precision oncology small molecule investigational therapy that selectively targets the p53 Y220C mutation.

• PMV Pharma will evaluate PC14586 in combination with Keytruda as a separate arm of the company's ongoing Phase 1/2 PYNNACLE trial in patients with advanced solid tumors.

• Approximately 36 patients are expected to be enrolled in the combination arm of the trial.

• This combination arm will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PC14586 in combination with Keytruda in patients with advanced solid tumors harboring a p53 Y220C mutation.

• Under the terms of the agreement, PMV Pharma will sponsor the trial, and Merck will supply Keytruda.

• PMV Pharma has conducted a series of experiments to evaluate the combination of p53 Y220C reactivators with checkpoint inhibitors. The combination showed an increase in anti-tumor activity and mean survival time in mouse tumor models, an improvement compared to either agent as monotherapy.

• Price Action: PMVP shares are down 2.55% at $15.56 during the market session on the last check Monday.

See more from Benzinga

• Merck Makes $290M Bet On Prostate Cancer Candidate

• The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.